Epsilon M&A Deal Report - Chanelle Pharma
Transaction Multiples for the Valuation of Private Companies
Private group led by Exponent Private Equity / Chanelle Pharma
No EMAT :
116340
Announced Date :
07/02/2024
Type :
LBO (Leverage Buy Out)
Deal Value :
Yes
Acquirer :
Private group led by Exponent Private Equity
Target :
Chanelle Pharma
Country :
Ireland
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Veterinary Pharmaceuticals
Business Description :
Founded in 1985 by Michael H Burke, Chanelle Pharma is the Ireland’s largest manufacturer of generic pharmaceuticals for animal and human health. > With a presence in over 80 countries, Chanelle...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
|
|
|
|
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
- Number of EMAT Reports / sub-sector « Veterinary Pharmaceuticals » = 34
| Date | Acquirer | Target | Country | Multiples | See details |
| 23/08/2021 | Vimian Group | Check-Points | Netherlands | ** | 116329 |
| 03/07/2023 | Novacyt | Yourgene Health | United Kingdom | ** | 116303 |
Source: Epsilon Research / EMAT
